LabSolutions Women’s Health testing takes advantage of the most advanced molecular technology available today to provide simple, appropriate, and actionable information as early as possible for the most common infections of the female genital tract. LabSolutions Women’s Health testing is comprised of tailored, infection-specific panels providing clinically relevant and results for various bacterial, fungal, and protozoal, viral, and mycoplasmal infections. These organisms are related to the development of bacterial vaginosis, candidal infections, leucorrhea, vaginitis, aerobic vaginitis, and genital ulcers.
Our Women’s Health panel looks for bacterial targets that can cause:
By screening for fungal targets, healthcare providers gain knowledge that can help them diagnose:
Mycoplasmas are surface parasites found in the urogenital and respiratory tracts. Our Women’s Health panel looks for mycoplasmal targets in order to screen for infections such as:
Screening for Trichomonas Vaginalis, a parasite that can be transmitted during sex, allows for an accurate diagnosis of the STD known as “trich” (trichomoniasis).
Trich is the most common curable STD according to the Centers for Disease Control and Prevention. Affecting women more than men, the symptoms can range from mild irritation to severe inflammation. Complications caused by trich can include an increased risk of spreading other STD’s such as HIV. Pregnant women with trich are more likely to have preterm delivery; babies born to infected mothers are at an increased risk of having a low birth weight.
By looking for viral targets Herpes Simplex 1 and 2, the Women’s Health panel provides information needed to diagnose oral and genital herpes.
Learn about the CDC’s guidelines on preventing STD’s here: STD Information from the CDC
The determination of antimicrobial susceptibility of a clinical isolate is often crucial to determine the optimal antimicrobial therapy of infected patients. This need is only increasing with increasing resistance and the emergence of multidrug-resistant microorganisms among the population being tested for infection. The report as provided by LabSolutions offers guidance to clinicians when determining the ideal pharmacological route to treat their patients.